Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03689192 · OUTCOME

4.Progression Free Survival

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors · Source last updated 2023-02-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
95% Confidence Interval
Time frame
0 - 75 weeks

What was measured

Progression free survival (PFS) defined as the time from treatment initiation to disease progression, relapse or death due to any cause, which ever comes first, will be described with Kaplan Meier curve. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Groups in this outcome

ARG1-18,19,20 Peptide Vaccine

One ARG1-vaccine every third week for 45 weeks. ARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ARG1-18,19,20 Peptide Vaccine10

Reported measurements

Source class 1
Values in days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
ARG1-18,19,20 Peptide Vaccine62Not reported34.785.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        34.7
        upper Limit
        85.3
        value
        62
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Progression free survival (PFS) defined as the time from treatment initiation to disease progression, relapse or death due to any cause, which ever comes first, will be described with Kaplan Meier curve. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
dispersion Type
95% Confidence Interval
groups
  1. description
    One ARG1-vaccine every third week for 45 weeks. ARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
    id
    OG000
    title
    ARG1-18,19,20 Peptide Vaccine
param Type
MEDIAN
reporting Status
POSTED
time Frame
0 - 75 weeks
title
4.Progression Free Survival
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice